Lessons from 'real life experience' of rifaximin use in the management of recurrent hepatic encephalopathy
| Autor: | Jean-Marie Péron, Marie-Angèle Robic, Maeva Guillaume, Fiona Chautant, Jean-François Cadranel, Christophe Bureau, Hortensia Lison, Charlène Cool, Véronique Duhalde |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Cirrhosis Rifaximin 03 medical and health sciences Liver disease chemistry.chemical_compound Lactulose 0302 clinical medicine Retrospective Study Internal medicine medicine Major complication Hepatic encephalopathy Hepatology business.industry Significant difference Retrospective cohort study medicine.disease Hospitalization chemistry 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | World Journal of Hepatology |
| ISSN: | 1948-5182 |
| Popis: | Background Hepatic encephalopathy (HE) is a major complication of cirrhosis with independent prognostic significance. The current management of HE is mainly based on lactulose. Rifaximin has been shown to decrease the risk of HE recurrence in patients with episodic forms. HE can also be persistent. However, there is no drug support recommendation for rifaximin use in this setting. Aim To assess the effectiveness of rifaximin in the management of recurrent episodes of HE and recurrent acute exacerbations on persistent HE, in "real life conditions". Methods In this retrospective study, using a within-subjects design, we collected data of patients treated with rifaximin for HE in two liver diseases centers, during the six-month period before and during the six-month period after the initiation of rifaximin. The primary effectiveness endpoint was the total number of HE events involving hospitalization. Results Rifaximin was introduced for prevention of recurrent HE episodes in 29 out of 62 patients with normal mental status between episodes and for prevention of recurrent acute exacerbations on persistent HE in 33 out of 62 patients. In the "prevention of recurrent HE episodes" group, fewer HE events (0.79 vs 1.78; P = 0.013) were reported during the period of time when rifaximin was used. In the "prevention of recurrent acute exacerbations on persistent HE" group, there was no significant difference in the number of HE-events (1.48 vs 1.77; P = 0.582). Conclusion In this real-life experience, the effectiveness of rifaximin was confirmed in the prevention of HE episodes recurrence but was not proved in the prevention of acute exacerbations recurrence on persistent HE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|